William Snider Purchases 8,475 Shares of Harvard Bioscience (NASDAQ:HBIO) Stock

Harvard Bioscience, Inc. (NASDAQ:HBIO) Director William Snider purchased 8,475 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The shares were bought at an average cost of $4.85 per share, with a total value of $41,103.75. Following the purchase, the director directly owned 32,000 shares of the company’s stock, valued at approximately $155,200. This represents a 36.03% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.

William Snider also recently made the following trade(s):

• On Monday, March 16th, William Snider acquired 12,525 shares of Harvard Bioscience stock. The stock was purchased at an average cost of $4.99 per share, for a total transaction of $62,499.75.

Harvard Bioscience Trading Up 14.8%

HBIO opened at $5.60 on Friday. The company has a quick ratio of 0.41, a current ratio of 2.20 and a debt-to-equity ratio of 2.61. The stock’s fifty day moving average is $5.57 and its two-hundred day moving average is $5.66. The company has a market capitalization of $25.04 million, a P/E ratio of -0.44 and a beta of 1.51. Harvard Bioscience, Inc. has a 52 week low of $2.81 and a 52 week high of $9.50.

Institutional Investors Weigh In On Harvard Bioscience

Hedge funds have recently made changes to their positions in the stock. Essex Investment Management Co. LLC bought a new stake in Harvard Bioscience during the fourth quarter valued at about $124,000. Strs Ohio bought a new position in Harvard Bioscience in the first quarter worth about $117,000. Bank of America Corp DE lifted its position in shares of Harvard Bioscience by 44.4% during the fourth quarter. Bank of America Corp DE now owns 38,883 shares of the medical instruments supplier’s stock valued at $82,000 after buying an additional 11,948 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of Harvard Bioscience during the second quarter valued at about $61,000. Finally, Virtu Financial LLC bought a new stake in shares of Harvard Bioscience in the 4th quarter valued at about $40,000. 80.87% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on HBIO. Benchmark cut their price target on Harvard Bioscience from $20.00 to $6.00 and set a “speculative buy” rating on the stock in a research note on Friday, March 13th. New Street Research set a $6.00 target price on shares of Harvard Bioscience in a report on Friday, March 13th. Zacks Research raised shares of Harvard Bioscience to a “hold” rating in a research report on Thursday, December 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Harvard Bioscience in a research note on Monday, December 29th. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $6.00.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.